The US Food and Drug Administration (FDA) announced the side effects of Legongqing. According to the report of adverse reactions after the drug is marketed, it is found that patients taking this kind of neuraminidase inhibitor drugs may cause mental disorders or strange behaviors and other adverse reactions, thus causing patients to be hurt. Most of these case reports are from Japan. Therefore, drug dealers have published these post-marketing experiences in the warnings and precautions of the drug imitation list. In the United States, the Food and Drug Administration reminds flu patients that they should closely monitor users' behavior after taking medicine, seek medical attention as soon as possible if neuropsychiatric symptoms appear, and evaluate the risks and benefits of taking medicine.
The drug is a monitored drug, and drug dealers need to submit the safety information of drugs after listing regularly according to regulations. In the data notified by ADR notification center, there are no reported cases of suspected behavior change due to the use of Legonqing drugs in China.